Multiple sclerosis is an inflammatory, demyelinating disease of the central nervous system (CNS) that affects more than one million people worldwide. It is believed to be an autoimmune disease in which exposure of genetically predisposed people to environmental factors triggers a breakdown in T cell tolerance to myelin antigens. The specific types of myelin-specific T cells that contribute to the pathogenesis of multiple sclerosis are not known. Most studies have focused on the pathogenic role of myelin-specific CD4 + T cells because of the relatively strong association of susceptibility to multiple sclerosis with major histocompatibility complex (MHC) class II alleles. In addition, CD4 + T cells are the main effector T cells in experimental autoimmune encephalomyelitis (EAE), a widely used animal model of multiple sclerosis. However, there is increasing recognition of the potential importance of CD8 + T cells in the pathogenesis of multiple sclerosis. CD8 + T cells typically outnumber CD4 + T cells in acute and chronic lesions of patients with multiple sclerosis, and the CD8 + T cell subset shows more evidence of antigen-driven activation than do CD4 + T cells in the CNS and blood of patients with multiple sclerosis 1, 2 . The frequency of neuroantigen-specific CD8 + T cells, but not CD4 + T cells, in the CNS is also higher in patients with multiple sclerosis than in healthy controls 3 . Furthermore, depletion of CD4 + T cells is not beneficial to patients with multiple sclerosis, whereas depletion of a broader spectrum of leukocytes, including both CD4 + T cells and CD8 + T cells, diminishes lesion formation and relapses 4 . Together these observations support the idea of a role for both CD4 + myelin-specific T cells and CD8 + myelin-specific T cells in the pathogenesis of multiple sclerosis.
The conditions that lead to a loss of tolerance in either myelinspecific CD4 + or CD8 + T cells are not known. Genome-wide association studies have identified many multiple sclerosis-susceptibility alleles, each of which (apart from HLA-DR2) seems to contribute only slightly to the risk of developing multiple sclerosis 5 . This genetic complexity, together with the variability in the pathology, symptoms and clinical course of multiple sclerosis, suggest the possibility of multiple disease-initiating pathways. Disease heterogeneity may account for the difficulty in identifying environmental triggers of multiple sclerosis. Although viral infections have long been proposed to initiate the disease process [6] [7] [8] [9] , linkage of a particular virus to the pathogenesis of multiple sclerosis has not yet been achieved. Association with a specific infection is particularly difficult for a multifactorial disease such as multiple sclerosis because a ubiquitous infection may trigger disease in only a small fraction of infected people depending on the diverse interactions of their particular susceptibility alleles with the environment.
Few animal models exist in which infectious triggers of CNS autoimmunity can be investigated. Infection with Theilers murine encephalomyelitis virus (TMEV), another model of multiple sclerosis, has been shown to induce CNS autoimmunity by causing bystander activation of myelin-specific CD4 + T cells 10 . However, no model has been described in which an infectious agent abrogates tolerance in myelin-specific CD8 + T cells. Here we used a MHC class I-restricted TCR-transgenic model that generates CD8 + T cells specific for myelin basic protein (MBP) to investigate conditions that break CD8 + T cell tolerance and induce CNS autoimmunity. Two TCR-transgenic models expressing distinct TCRs specific for residues 79-87 of MBP (MBP(79-87)) presented by the H-2K k MHC molecule have been generated 11 . Mice expressing a transgenic TCR composed of α-chain variable region 8 (V α 8) and V β 6 (8.6 mice) show both central and
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Multiple sclerosis is an inflammatory, demyelinating, central nervous system disease mediated by myelin-specific T cells. Environmental triggers that cause the breakdown of myelin-specific T cell tolerance are unknown. Here we found that CD8 + myelin basic protein (MBP)-specific T cell tolerance was broken and autoimmunity was induced by infection with a virus that did not express MBP cross-reactive epitopes and did not depend on bystander activation. Instead, the virus activated T cells expressing dual T cell antigen receptors (TCRs) that were able to recognize both MBP and viral antigens. Our results demonstrate the importance of dual TCR-expressing T cells in autoimmunity and suggest a mechanism by which a ubiquitous viral infection could trigger autoimmunity in a subset of infected people, as suggested by the etiology of multiple sclerosis.
peripheral tolerance, consistent with the constitutive presentation of MBP in lymphoid and other tissues. In contrast, T cells expressing a transgenic TCR composed of V α 8 and V β 8 (8.8 mice) escape central and peripheral tolerance, although they proliferate vigorously in response to MBP(79-87) peptide in vitro. This split tolerance has also been observed for several MHC class II-restricted MBP-specific TCR-transgenic models in which the low avidity of the interactions between the MBP-specific T cells and their ligand prevents responses to endogenous MBP in vivo, although the T cells can respond to MBP peptide in vitro. Tolerance in MHC class II-restricted TCR-transgenic models is broken at some stochastic frequency, as spontaneous EAE can occur, especially in the absence of regulatory T cells 12, 13 . Disease is also easily induced in MHC class II-restricted TCR-transgenic models by immunization protocols that induce CD4 + T cell-mediated EAE in wild-type mice. The tolerance maintained by CD8 + T cells in 8.8 mice differs from that of MBP-specific CD4 + T cells in that 8.8 T cells show high avidity for their ligand and seem to remove the ligand from antigen-presenting cells (APCs) without triggering T cell activation 11 . This observation suggests that the circumstances that lead to loss of tolerance may differ for CD8 + MBP-specific T cells and CD4 + MBP-specific T cells.
Our studies here show that many conditions that induce disease in MHC class II-restricted myelin-specific TCR-transgenic models failed to break tolerance in CD8 + 8.8 T cells. CNS autoimmunity in 8.8 mice was triggered by infection with a recombinant vaccinia virus encoding MBP (Vac-MBP), consistent with the ability of viruses to efficiently prime MHC class I-restricted T cells. Unexpectedly, infection with wild-type vaccinia virus also triggered CNS autoimmunity as efficiently as infection with Vac-MBP despite a lack of cross-reactivity between the 8.8 TCR and viral epitopes. Disease induction by wild-type virus required the expression of endogenous TCR chains on the 8.8 T cells. Our results demonstrate a role for dual TCRs in the initiation of CNS autoimmune disease and suggest a previously unknown mechanism by which a ubiquitous viral infection may trigger disease in only a subset of infected people.
RESULTS
Tolerance differs in CD8 + and CD4 + MBP-specific T cells
In contrast to MHC class II-restricted MBP-specific TCR-transgenic models, MBP-specific 8.8 mice did not develop spontaneous EAE, even on the recombination-activating gene 2-deficient (Rag2 −/− ) background (0 of 198 Rag2 +/+ 8.8 mice and 0 of 24 Rag2 −/− 8.8 mice observed for more than 12 weeks). This result indicated that regulatory T cells, which were absent from the Rag2 −/− 8.8 mice (data not shown), were not required to prevent 8.8 T cells from responding to endogenous MBP. We investigated the susceptibility of 8.8 mice to active disease induction by using a protocol that efficiently induces EAE in MHC class II-restricted MBP-specific TCR-transgenic models and has also been shown to induce autoimmune disease in a published MHC class I-restricted TCR-transgenic humanized mouse model of multiple sclerosis in which the transgenic CD8 + T cells recognize a MHC class I-restricted epitope of proteolipid protein (PLP) 14 .
We observed no neurological signs in 8.8 mice immunized with MBP(79-87) in complete Freund's adjuvant with or without injection of pertussis toxin ( Supplementary Table 1 ). To assess whether peptide immunization is an efficient protocol for activating CD8 + 8.8 T cells, we labeled 8. (Supplementary Fig. 1 ). To determine if 8.8 T cell tolerance could be abrogated by strong, widespread activation of the APCs that present endogenous MBP throughout the animal, we administered lipopolysaccharide (LPS) and agonistic antibody to CD40 (anti-CD40) to 8.8 mice. Neither reagent, alone or in combination, induced disease in 8.8 mice. Likewise, we observed no disease in 8.8 mice treated with polyinosinic-polycytidylic acid ( Supplementary  Table 1 ). However, we observed weight loss and mild neurological signs in 8.8 mice when we injected MBP(79-87) simultaneously with both LPS and anti-CD40 ( Supplementary Fig. 2 and Supplementary Table 1 ). Injection of MBP(79-87) alone had no effect. These results suggest that both strongly activating APCs in multiple tissues and increasing the concentration of ligand above the amount generated from endogenous MBP are needed to break 8.8 T cell tolerance in vivo.
Viral infection triggers autoimmunity in 8.8 mice
The conditions for breaking 8.8 T cell tolerance described above suggested that CD8 + T cell-mediated autoimmunity might be triggered by a viral infection that causes both widespread APC activation and generates de novo expression of a self antigen mimic. Consistent with that hypothesis, we found that 8.8 mice showed 100% incidence of autoimmune disease after infection with Vac-MBP. Unexpectedly, we also found that 8.8 mice infected with wild-type vaccinia virus showed the same incidence and severity of disease A r t i c l e s ( Fig. 1a and Supplementary Table 1 ). In both groups of mice, the disease was characterized by weight loss and clinical signs such as ataxia, knuckling, difficulty walking and tail weakness. The clinical course of disease is presented here as increasing weight loss as this is the most quantitative measure of disease progression; however, immunochemical analysis demonstrated infiltration of CD8 + T cells and F4/80 + macrophages and activated microglia in both the brain and spinal cord of 8.8 mice infected with wild-type vaccinia virus, as expected for an autoimmune disease targeting the CNS (Supplementary Fig. 3 ). The disease progressed rapidly and we killed most mice 9 d after infection. In some experiments, mice survived this acute disease and developed chronic neurological symptoms such as walking difficulty and tail weakness (Supplementary Video 1).
Analysis of viral titers in lymphoid organs and the CNS after infection showed that 8.8 mice cleared vaccinia virus as efficiently as wildtype mice did (data not shown), which indicated that the disease was not due to poor viral clearance in the TCR-transgenic mice. The idea of effective viral clearance in 8.8 TCR-transgenic mice was supported by the absence of clinical signs in Mbp −/− 8.8 mice infected with wild-type vaccinia virus ( Fig. 1a and Supplementary Table 1 ). Infection with wild-type vaccinia virus activated a population of 8.8 T cells in vivo identified by lower fluorescence intensity of staining for MBP-H-2K k tetramer and CD62L and higher CD44 expression than that of uninfected mice (Fig. 1b) . These cells acquired effector function, as MBP-pulsed splenocytes were specifically lysed when transferred into vaccinia virus-infected 8.8 mice but not when transferred into naive 8.8 mice ( Fig. 1c) . We observed accumulation of 8.8 T cells in the CNS of vaccinia virus-infected Mbp +/+ 8.8 mice but not Mbp −/− 8.8 mice, and this correlated with neurological symptoms (Fig. 1d) .
These data indicate that infection with wild-type vaccinia virus breaks 8.8 T cell tolerance and promotes an autoimmune response directed against endogenous MBP in the CNS. Viral infections have been proposed to trigger autoimmune disease via several mechanisms. Bystander activation of self-reactive T cells might occur if a viral infection caused the release of sequestered autoantigens into an inflammatory milieu. To test that possibility, we infected Mbp −/− 8.8 mice with wild-type vaccinia virus and analyzed T cells for activation markers and their ability to lyse MBP-pulsed splenocytes in vivo. As observed for Mbp +/+ 8.8 mice, infection with vaccinia virus induced a population of activated 8.8 T cells in Mbp −/− mice that specifically lysed MBP-pulsed target cells in vivo (Fig. 2) . These results indicate that infection with vaccinia virus does not activate 8.8 T cells via a bystander mechanism, because the 8.8 T cells were activated in the absence of endogenous MBP.
Molecular mimicry could also account for the ability of wild-type vaccinia virus to induce disease in 8.8 mice if the 8.8 TCR showed cross-reactivity to a viral antigen. In vitro experiments did not support this possibility, as 8.8 T cells proliferated in response to splenocytes infected with Vac-MBP but not those infected with wild-type vaccinia virus (data not shown). To explore this possibility in vivo, we transferred genetically marked, wild-type splenocytes into Rag2 −/− 8.8 mice before infecting the mice with wild-type vaccinia virus to provide the B cells and nontransgenic T cells needed for viral clearance. At 7 d after infection, we stimulated splenocytes from the infected mice in vitro with vaccinia virus-infected target cells and analyzed T cell responses by intracellular staining for interferon-γ (IFN-γ; Fig. 3 ). We detected IFN-γ secretion only in the CD8 + T cell population derived from nontransgenic donor splenocytes and not in the host Rag2 −/− 8.8 T cells, which demonstrated the inability of the 8.8 TCR to recognize viral antigens.
The 8.8 T cells are activated via endogenous TCR chains
The lack of IFN-γ production by Rag2 −/− 8.8 T cells in response to vaccinia virus-infected target cells suggested that Rag2 −/− 8.8 T cells differed from Rag2 +/+ 8.8 T cells in that they were not activated during infection with vaccinia virus. Therefore, we sought to determine if Rag2 −/− 8.8 mice were susceptible to autoimmune disease induced by infection with wild-type vaccinia virus. We transferred wild-type splenocytes into Rag2 +/+ and Rag2 −/− 8.8 mice before infecting the recipients with wild-type vaccinia virus, and then monitored them for clinical signs. A r t i c l e s autoimmune disease, none of the Rag2 −/− 8.8 recipients developed disease ( Fig. 4a and Supplementary Table 1) . Consistent with the lack of disease induction, Rag2 −/− 8.8 T cells did not acquire effector function as a result of infection with wild-type vaccinia virus, as MBP-pulsed splenocytes were lysed only after transfer into infected Rag2 +/+ 8.8 recipients and not after transfer into infected Rag2 −/− 8.8 recipients (Fig. 4b) . This result, together with the fact that the Rag2 −/− 8.8 mice contained nontransgenic T cells and B cells before infection, indicates the involvement of an intrinsic difference in Rag2 −/− versus Rag2 +/+ 8.8 T cells in conferring susceptibility to virus-induced autoimmunity.
Peripheral T cells in Rag2 +/+ 8.8 mice are skewed toward the CD8 + subset; however, some CD4 + V α 8 + V β 8 + T cells also develop. In contrast, T cells in Rag2 −/− 8.8 mice are all CD4 − CD8 + . To determine if the inability of wild-type vaccinia virus to induce autoimmunity in Rag2 −/− 8.8 mice was due to the loss of CD4 + 8.8 T cells, we treated Rag2 +/+ 8.8 mice with depleting antibody to CD4 before infecting them with vaccinia virus. We found that 8.8 mice depleted of CD4 + T cells showed a delayed onset and somewhat milder disease, but the incidence of autoimmunity was not lower in mice lacking CD4 + T cells ( Supplementary Fig. 4a and Supplementary Table 1 ). The lower disease severity in CD4 + T cell-depleted, vaccinia virusinfected 8.8 mice could have been due to a loss of pathogenic CD4 + 8.8 T cells or to a loss of help provided by CD4 + T cells to activated CD8 + 8.8 T cells. The latter possibility was supported by the finding that adoptive transfer of 8.8 T cells stimulated with MBP(79-87) in vitro induced autoimmunity only when interleukin 2 (IL-2) was administered after T cell transfer (data not shown). To determine if CD4 + 8.8 T cells were pathogenic, we purified CD4 + T cells and CD8 + T cells from Rag2 +/+ 8.8 mice, stimulated them in vitro with MBP(79-87) and adoptively transferred them into naive recipients, accompanied by injections of IL-2. Although all recipients of CD8 + 8.8 T cells succumbed to autoimmunity, none of the recipients of CD4 + 8.8 T cells showed weight loss or clinical signs ( Supplementary  Fig. 4b) . These results indicate that the ability of vaccinia virus to induce disease in Rag2 +/+ 8.8 mice does not depend on the presence of CD4 + 8.8 T cells.
The other main difference between Rag2 +/+ and Rag2 −/− 8.8 T cells is the potential for Rag2 +/+ 8.8 T cells to express endogenous TCR chains because of the incomplete allelic exclusion of rearrangements of Tcra and Tcrb. Indeed, expression of dual TCRs containing endogenous TCR β-chains paired with transgenic TCR α-chains or endogenous TCR α-chains paired with transgenic TCR β-chains has been observed on peripheral T cells in several TCR-transgenic models [15] [16] [17] [18] . The possibility that expression of endogenous TCR chains on 8.8 T cells is required for susceptibility to wild-type virusinduced autoimmune disease suggested the hypothesis that vaccinia virus breaks 8.8 T cell tolerance by triggering T cell activation via a virus-specific TCR coexpressed with the MBP-specific TCR on 8.8 T cells. If this mechanism is correct, infected 8.8 mice should be more enriched for CD8 + T cells coexpressing the 8.8 TCR with particular endogenous TCR αand/or β-chains that confer specificity to viral antigens than uninfected 8.8 mice. To test that hypothesis, we compared the expression of a panel of TCR V β chains on CD8 + T cells isolated from naive Rag2 +/+ 8.8 mice and Rag2 +/+ 8.8 mice infected with wild-type vaccinia virus. Although none of the antibodies specific for endogenous V β chains detected populations of more than 1% of CD8 + T cells in uninfected 8.8 mice (data not shown), T cell populations coexpressing V β 8 and V β 6 expanded after infection with vaccinia virus (Fig. 5a) . The absolute number of V β 8 + V β 6 + T cells in the spleen was over 40-fold more in infected 8.8 mice (n = 4) than in naive 8.8 mice (n = 8; P = 0.004). In contrast to the naive phenotype of V β 8 hi V β 6 − T cells, V β 8 + V β 6 + T cells had an activated phenotype in infected mice (Fig. 5b) . To investigate the antigen specificity associated with V β 6 expression, we isolated T cells from vaccinia virus-infected 8.8 mice, restimulated the cells in vitro with vaccinia virus-infected splenocytes or MBP-pulsed splenocytes and analyzed IFN-γ production and V β 6 expression. More than 50% of the T cells that produced IFN-γ in response to splenocytes infected with wild-type vaccinia virus expressed V β 6, whereas only 9.6% of the T cells that produced IFN-γ in response to MBP-pulsed splenocytes were V β 6 + (Fig. 5c) , which indicated that coexpression of V β 6 + 'preferentially' conferred specificity for viral antigens. To determine if 8.8 T cell populations coexpressing particular V α chains also expanded in response to infection with A r t i c l e s vaccinia virus, we sorted T cells with either a naive or activated phenotype from infected 8.8 mice and analyzed their expression of various V α chains by real-time PCR. Activated T cells isolated from infected mice had enriched expression of V α 11, V α 13 and V α 14 compared with that of naive T cells isolated from infected mice (Supplementary Fig. 5 ). Together these data indicate that T cell populations coexpressing the 8.8 TCR and specific endogenous TCR chains are expanded in response to infection with vaccinia virus and that activation of these T cells correlated with loss of 8.8 T cell tolerance and the induction of autoimmune disease. This mechanism allows the prediction that other viral infections would trigger autoimmunity in 8.8 mice, which was supported by our finding that infection with adenovirus also induced autoimmunity in Rag2 +/+ 8.8 mice (Supplementary Table 1) .
Vac-MBP activates 8.8 T cells via the MBP-specific TCR
Our experiments in which we administered MBP(79-87), LPS and anti-CD40 in vivo demonstrated that the 8.8 T cells can be activated via the MBP-specific TCR if the APCs are strongly activated and the dose of MBP increases above endogenous amounts. Therefore, we sought to determine whether infection with Vac-MBP could induce disease in Rag2 −/− 8.8 mice. Rag2 −/− 8.8 T cells proliferated in vivo in response to Vac-MBP-infected cells but not in response to cells infected with wild-type vaccinia virus (Fig. 6a) . In contrast to our results obtained after infection with wild-type vaccinia virus, Rag2 −/− 8.8 mice that received the wild-type splenocytes needed to clear the virus succumbed to autoimmune disease after infection with Vac-MBP ( Fig. 6b and Supplementary Table 1 ). This result demonstrates that viral infection can break 8.8 T cell tolerance via signaling through the MBP-specific TCR if the infection causes both higher expression of MBP and widespread APC activation.
DISCUSSION
In the present study, we have demonstrated that viral infection triggered CD8 + T cell-mediated autoimmune disease in the CNS by two distinct mechanisms. Infection with Vac-MBP induced disease via a 'molecular identity' mechanism in which the virus encoded an epitope recognized directly by the MBP-specific TCR. In contrast, infection with wild-type vaccinia virus broke tolerance in T cells that expressed dual TCRs due to incomplete allelic exclusion of the Tcra or Tcrb locus. Activation via a coexpressed virus-specific TCR overcame the lack of response of the MBP-specific 8.8 TCR to endogenous MBP such that the T cell was able to respond to both the viral epitope and endogenous MBP. Viral infection has long been postulated to be an environmental factor that contributes to the etiology of multiple sclerosis. Although several different viruses have been linked to this over the years 19, 20 , no specific virus has been confirmed as being a causative agent in the pathogenesis of multiple sclerosis. Because it is a multifactorial disease 5 , it is possible that multiple viruses influence susceptibility to multiple sclerosis, and the ability of any particular virus to contribute to the pathogenesis of this disease may be dependent on the repertoire of susceptibility alleles each person carries and their exposure to other predisposing environmental factors. Alternatively, multiple sclerosis may be triggered by a common infection that initiates disease in only a small fraction of infected people, as suggested by the geographical distribution of multiple sclerosis and the change in risk observed in migrants. In particular, a large body of evidence accumulated over the past two decades indicates that the human herpes virus Epstein-Barr virus (EBV) is a risk factor in the development of multiple sclerosis that operates independently of the risk contributed by the MHC DR15 allele [20] [21] [22] [23] . Data from many studies have shown that the risk of developing multiple sclerosis is 15 times higher in EBV + people than in EBV − people and is two-to threefold higher in people with a history of infectious mononucleosis than in people who experienced asymptomatic infection 24, 25 .
Animal models of multiple sclerosis induced by viral infection have identified some mechanisms by which viruses could trigger CNS autoimmunity. Infection with murine hepatitis virus induces a chronic, demyelinating disease that depends only on the activity of virus-specific T cells rather than on the emergence of myelin-specific T cells during the course of infection 26 . In contrast, TMEV induces CNS autoimmune disease in susceptible mouse strains via bystander activation of myelin antigen-specific CD4 + T cells. Bystander activation is facilitated by myelin damage that occurs during the initial clearance of virus by CD8 + T cells, which results in presentation of myelin epitopes by APCs to CD4 + myelin antigen-specific T cells that were nonspecifically recruited to the CNS. This phenomenon of epitope spreading from viral antigen-specific CD8 + T cells to self-reactive, myelin-specific CD4 + T cells results in a chronic disease that resembles multiple sclerosis 27 . A different mechanism has been demonstrated for recombinant TMEV encoding either a peptide derived from Haemophilus influenzae that shares six of 13 amino acids with a peptide from PLP(139-151) or a peptide derived from murine hepatitis virus sharing only three amino acids with PLP(139-151) 28, 29 . In these cases, the molecular mimicry between H. influenzae or murine hepatitis virus peptide and PLP peptide is sufficient to prime PLP(139-151)-specific CD4 + T cells, which then initiate chronic disease. Autoreactive CD8 + T cell clones have also been isolated from mice infected with the DA strain of TMEV, and these clones induce CNS pathology after adoptive transfer into uninfected mice 30 . However, the self antigen recognized by these CD8 + T cell clones has not been identified. Infection with Semliki Forest virus also induces an inflammatory, demyelinating disease in the CNS in which both virus-specific T cells and antibodies are generated that cross-react with myelin epitopes 31 .
In contrast to those models, our studies have demonstrated mechanisms by which viral infection broke tolerance directly in CD8 + MBPspecific T cells. Vac-MBP triggered autoimmunity in Rag2 −/− 8.8 mice by a mechanism analogous to molecular mimicry in that an epitope encoded by the virus was specifically recognized by the MBP-specific TCR. The context of viral infection was important in breaking the tolerance normally maintained in vivo when the 8.8 TCR engages endogenous MBP ligand, as immunization with MBP(79-87) in complete Freund's adjuvant was not sufficient to induce disease in 8.8 mice. This result differs from findings in MHC class I-restricted PLP-specific TCR-transgenic mice in which neurological signs could be induced by immunization with PLP peptide 14 . The clinical signs induced by this immunization were very mild and CD4 + T cell activity was required for further disease progression and relapses. The differences in the requirement for CD4 + T cells and the severity of disease in that model relative to that of our model may reflect differences in the tolerance mechanisms that allow the CD8 + PLP-specific and MBP-specific 8.8 T cells to circulate in the periphery as naive T cells. Furthermore, CD4 + T cell help is not needed to activate naive CD8 + T cells during viral infection. The administration of LPS and agonistic anti-CD40 also did not induce disease in 8.8 mice, even though this method of activating APCs presenting endogenous MBP breaks tolerance in some CD4 + MBP-specific TCR-transgenic T cells 32 . Mild disease was induced by coadministration of MBP(79-87) with LPS and agonistic anti-CD40, which indicated that the epitope stripping that normally maintains 8.8 T cell tolerance can be overcome when there is both widespread activation of APCs and an increase in the concentration of the MBP ligand. These conditions were achieved more efficiently by infection with Vac-MBP, which accounted for the greater ability of Vac-MBP infection to induce disease in 8.8 mice than coadministration of MBP(79-87) with LPS plus anti-CD40.
Unexpectedly, we found that infection of Rag2 +/+ 8.8 mice with wild-type vaccinia virus also induced autoimmunity. In contrast to infection with TMEV, infection with this virus does not induce CNS autoimmunity by bystander activation or by molecular mimicry. Notably, Rag2 −/− 8.8 mice infected with wild-type vaccinia virus were not susceptible to autoimmune disease. The lack of disease in Rag2 −/− 8.8 mice did not reflect a requirement for the CD4 + 8.8 T cells that are eliminated on the Rag2 −/− background. Instead, our data have shown that expression of endogenous TCR chains on 8.8 T cells was required for wild-type vaccinia virus to induce disease in 8.8 mice. Consistent with the hypothesis that 8.8 T cells are activated via a viral antigen-specific TCR coexpressed with the 8.8 TCR, a population of T cells coexpressing the 8.8 TCR and V β 6 expanded after vaccinia virus infection, and this population was specifically enriched for T cells that responded to viral antigens. CD4 + V β 6 + T cell populations did not expand after infection of 8.8 mice (data not shown), which indicated that the virus does not function as a superantigen that activates T cells expressing particular V β chains independently of antigen specificity. After infection with vaccinia virus, the activated T cell population showed greater enrichment for T cells expressing V α 11, V α 13 and V α 14 than did the nonactivated T cell population. We conclude from these data that wild-type vaccinia virus breaks 8.8 T cell tolerance by triggering T cell activation via virus-specific TCRs that are coexpressed with the 8.8 MBP-specific TCR.
The ability to activate 8.8 T cells via a second TCR indicated that the effector functions of 8.8 T cells were intact despite their lack of response to endogenous MBP. Similarly, in mice engineered to express two transgenic TCRs, one of which induces strong anergy in vivo after interaction with a neo self antigen, stimulation via the second transgenic TCR activates the anergic T cells 33 . Our model differed from that in that the 8.8 T cells were specific for a true self antigen linked to the pathogenesis of multiple sclerosis and were not subjected to clonal deletion or anergy in vivo 11 .
Although our model used TCR-transgenic mice, T cells expressing dual TCRs exist in both mice and humans. Dual-TCR T cells usually express one TCR β-chain and two α-chains because allelic exclusion is less complete for the Tcra locus. In mice, the percentage of T cells reported to express two TCR α-chains varies from 2% to 15% (refs. [34] [35] [36] , and a 33% frequency has been reported for humans 37 . The frequency of T cells expressing two TCR β-chains is estimated to be ~1% in humans and 3% in mice, with the frequency increasing with age 16, 38, 39 . Although our data did not distinguish the specific pairing of TCR chains that compose virus-specific TCRs in 8.8 mice, it is more likely that a second TCR is generated in 8.8 T cells by pairing of an endogenous α-chain with the transgenic β-chain or pairing of an endogenous β-chain with the transgenic α-chain rather than via a failure of allelic exclusion at both the Tcra and Tcrb loci in individual transgenic T cells.
Peripheral T cells expressing dual TCRs have been shown to be beneficial by expanding the repertoire of T cells that respond to foreign antigens 40 . Since the first demonstration of T cells expressing two α-chains on the cell surface, however, most studies have focused on the hypothesis that expression of dual TCRs may promote autoimmunity and alloreactivity 18, 41 . Support for the idea of a substantial contribution to alloreactivity has been provided by studies demonstrating that dual-TCR T cells have a dominant role in graft-versus-host disease 42 . In contrast, studies of animal models of autoimmune disease, including collageninduced arthritis, EAE and diabetes, have failed to show any role for dual-TCR T cells in autoimmunity 35, 43, 44 . The frequency of spontaneous EAE in MHC class II-restricted MBP-specific TCR-transgenic mice increases when microbial exposure in the environment increases 12, 45 ; however, a role for dual TCRs responding to environmental antigens could not be established in the model in those studies 12, 45 because the loss of regulatory T cells on the Rag2 −/− background considerably enhances the incidence of spontaneous EAE 46 . Thus, the studies reported here are the first to our knowledge to show a mechanism for triggering autoimmune disease that depends on the expression of dual TCRs.
Our findings suggest a new perspective on the proposed virusinduced etiology of multiple sclerosis that is consistent with the inability to detect infectious virus in the CNS. As the frequency of T cells coexpressing a myelin-specific TCR and a virus-specific TCR in the peripheral T cell repertoire should be low and probably varies among people, this mechanism may represent one way a common infection can trigger autoimmunity in a small subset of genetically predisposed people. The cumulative data on the connection between EBV infection and multiple sclerosis are consistent with this hypothesis. Despite the association of multiple sclerosis with higher serum titers of antibodies specific for EBV-encoded nuclear antigen 1 (ref. 29 ) and with a greater frequency of EBV-specific CD4 + and CD8 + T cells 21 , the evidence for an association of lytic EBV replication with multiple sclerosis is controversial. A published study has reported an incidence of almost 100% of EBV infection in CNS B cells from patients with multiple sclerosis, as well as viral reactivation in B cells present in CNS follicles accompanied by accumulation of activated CD8 + T cells 47 , which suggests that reactivation of EBV is a key factor in multiple sclerosis pathogenesis. However, the detection of EBV DNA in the CNS of patients with multiple sclerosis was not reproduced in another study using highly sensitive techniques 48 , which suggests that the function of EBV as a risk factor for multiple sclerosis is not dependent on reactivation of the virus during autoimmune disease. That idea is consistent with our conclusion that viral infection can activate T cells expressing dual TCRs, one specific for a viral epitope and one specific for a myelin epitope, which then drive the autoimmune process independently of an ongoing immune response to the pathogen. The low probability of this event may account not only for the low incidence of autoimmunity among people infected with one common pathogen but also for the higher antibody titers for several other common viruses in patients with multiple sclerosis 21 .
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureimmunology/.
Note: Supplementary information is available on the Nature Immunology website.
